Regulatory Compliance and Quality Assurance in Contract Manufacturing Organizations (CMOs): Issues and Solutions

Background: Contract manufacturing organizations (CMOs) produce a large and growing share of the world's medicines, yet they remain over-represented in regulatory enforcement. This study asks which compliance and quality assurance problems recur at CMOs, why they recur, and what practical controls would reduce them. Methods: A mixed-methods design combined (i) a retrospective classification of 214 USFDA Warning Letters issued to contract manufacturing sites between January 2019 and December 2025 into eight deficiency categories, and (ii) a cross-sectional online survey of 88 quality assurance, quality control and regulatory affairs professionals with CMO or CDMO experience. Data were analysed with descriptive statistics, Pareto analysis, cross-tabulation and chi-square testing (α = 0.05). Results: Data integrity and computerised systems were cited in 68.7% of letters (76% in 2025, up from 61% in 2019-20), followed by laboratory controls and OOS investigation (60.3%). Survey respondents attributed data integrity risk mainly to inadequate audit trail review resourcing (69.3%) and shared logins (61.4%). Only 35.2% performed effectiveness checks on all CAPAs, and fewer than half had quality agreements that set change-notification (44.3%) or deviation escalation (40.9%) timelines. Self-assessed quality system maturity rose with organization size in every element measured; 39.4% of small-organization respondents scored below the scale midpoint on a composite index, against 4.2% of large-organization respondents. Conclusions: The leading problems are systemic (resourcing, system design, and sponsor-CMO governance) rather than individual. Four tools are proposed: a CMO-specific risk-scoring matrix, a model quality technical agreement clause set, a four-layer data integrity governance model and a ten-point self-inspection checklist, delivered through a phased twelve-month roadmap sized for resource-constrained CMOs.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24300292
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Regulatory Compliance and Quality Assurance in Contract Manufacturing Organizations (CMOs): Issues and Solutions

RAJESH NAGAR, Shikhar Rathore, Kalpesh Sonwane
1 links
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Regulatory Compliance and Quality Assurance in Contract Manufacturing Organizations (CMOs): Issues and Solutions

RAJESH NAGAR, Shikhar Rathore, Kalpesh Sonwane
article en

Abstract

Background: Contract manufacturing organizations (CMOs) produce a large and growing share of the world's medicines, yet they remain over-represented in regulatory enforcement. This study asks which compliance and quality assurance problems recur at CMOs, why they recur, and what practical controls would reduce them. Methods: A mixed-methods design combined (i) a retrospective classification of 214 USFDA Warning Letters issued to contract manufacturing sites between January 2019 and December 2025 into eight deficiency categories, and (ii) a cross-sectional online survey of 88 quality assurance, quality control and regulatory affairs professionals with CMO or CDMO experience. Data were analysed with descriptive statistics, Pareto analysis, cross-tabulation and chi-square testing (α = 0.05). Results: Data integrity and computerised systems were cited in 68.7% of letters (76% in 2025, up from 61% in 2019-20), followed by laboratory controls and OOS investigation (60.3%). Survey respondents attributed data integrity risk mainly to inadequate audit trail review resourcing (69.3%) and shared logins (61.4%). Only 35.2% performed effectiveness checks on all CAPAs, and fewer than half had quality agreements that set change-notification (44.3%) or deviation escalation (40.9%) timelines. Self-assessed quality system maturity rose with organization size in every element measured; 39.4% of small-organization respondents scored below the scale midpoint on a composite index, against 4.2% of large-organization respondents. Conclusions: The leading problems are systemic (resourcing, system design, and sponsor-CMO governance) rather than individual. Four tools are proposed: a CMO-specific risk-scoring matrix, a model quality technical agreement clause set, a four-layer data integrity governance model and a ten-point self-inspection checklist, delivered through a phased twelve-month roadmap sized for resource-constrained CMOs.

Zenodo (CERN European Organization for Nuclear Research)
Oriental University (RU), Oriental Universiteti (UZ)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon